State Street SPDR S&P Telecom ETF (XTL)
Is State Street SPDR S&P Telecom ETF (XTL) a Strong ETF Right Now?
Making its debut on 01/26/2011, smart beta exchange traded fund State Street SPDR S&P Telecom ETF (XTL) provides investors broad exposure to the Communication Services ETFs category of the market.
XTL's Telecom Portfolio Offers Exceptional Returns, A Strong Buy For Aggressive Investors
State Street SPDR S&P Telecom ETF earns a strong buy rating, driven by 80% twelve-month price returns and robust AI-powered demand trends. XTL's portfolio is concentrated in high-growth communication equipment and alternative carrier industries, offsetting weakness in integrated and wireless telecom holdings. Top holdings like Viasat, Extreme Networks, and Ciena have delivered triple-digit or near-triple-digit returns, benefiting from secular AI and data center demand.
XTL Completed the Acquisition of Psyga Bio Ltd.
expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic juncture and with unprecedented regulatory tailwinds in the US, XTL completes its strategic transformation and becomes a dedicated company in the field of global psychedelic medicine; operations will focus on an advanced clinical pipeline, a licensed GMP manufacturing facility, and a unique intellectual property (IP) library. HERZLIYA, ISRAEL, June 30, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.
XTL Announces Receipt of Staff Delist Determination from Nasdaq
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies with Nasdaq's Listing Rule Listing Rule 5250(c)(1) which requires companies to timely file all required periodic financial reports with the SEC.
Is State Street SPDR S&P Telecom ETF (XTL) a Strong ETF Right Now?
Designed to provide broad exposure to the Communication Services ETFs category of the market, the State Street SPDR S&P Telecom ETF (XTL) is a smart beta exchange traded fund launched on 01/26/2011.
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum
Telecom ETF Hit a 52-Week High
Telecom ETF XTL hits a 52-week high, soaring about 149% from lows. Backed by 5G, AI-driven demand & defensive strength -- momentum suggests more upside ahead.
XTL: Amazon For Globalstar Is Just The Latest Catalyst
Amazon.com, Inc.'s $11.6 billion acquisition of Globalstar highlights surging demand for space-focused telecom, boosting XTL, where GSAT is the largest holding. I maintain a buy rating on the State Street SPDR S&P Telecom ETF, citing pristine momentum, an attractive 19.8x P/E, and a PEG near 1.0 amid a bullish technical setup. XTL's high small-cap exposure (60%) and low yield (0.95%) make it a tactical, growth-oriented telecom play rather than a defensive income vehicle.
XTL Biopharmaceuticals Announces ADS Ratio Change
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date").
Is State Street SPDR S&P Telecom ETF (XTL) a Strong ETF Right Now?
The State Street SPDR S&P Telecom ETF (XTL) was launched on 01/26/2011, and is a smart beta exchange traded fund designed to offer broad exposure to the Communication Services ETFs category of the market.
Telecom ETF (XTL) Touches New 52-Week High
For investors seeking momentum, the State Street SPDR S&P Telecom ETF XTL is probably on the radar now. The fund just hit a 52-week high and is up 126.8% from its 52-week low price of $85.16 per share.
SPDR S&P Telecom ETF (NYSEARCA:XTL) Short Interest Update
SPDR S&P Telecom ETF (NYSEARCA:XTL - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 26,577 shares, an increase of 94.9% from the January 29th total of 13,637 shares. Based on an average daily volume of 21,196
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company's American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision.
SPDR S&P Telecom ETF (NYSEARCA:XTL) Short Interest Up 110.6% in January
SPDR S&P Telecom ETF (NYSEARCA:XTL - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 34,617 shares, a growth of 110.6% from the December 31st total of 16,436 shares. Approximately 2.3% of the shares of the stock are sold short.
XTL Update on Recent Developments
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company's Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million.
4,441 Shares in SPDR S&P Telecom ETF $XTL Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors bought a new position in SPDR S&P Telecom ETF (NYSEARCA:XTL) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,441 shares of the company's stock, valued at approximately $621,000. Arkadios Wealth Advisors owned about 0.40% of SPDR
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. This Nasdaq determination was based on (i) the Company's Form 6-K, dated December 30, 2025, that included financial information for the period ended June 30, 2025, and which reported stockholders' equity deficit of $47,000, and (ii) that the Company does not meet the alternatives of market value of listed securities or net income from continuing operations as of January 20, 2026.
SPDR S&P Telecom ETF (NYSEARCA:XTL) Short Interest Up 59.9% in December
SPDR S&P Telecom ETF (NYSEARCA:XTL - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 16,436 shares, a growth of 59.9% from the December 15th total of 10,276 shares. Approximately 1.2% of the company's shares are sold
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.